Huiyu Pharmaceutical: Amend the 2025 annual performance report, confirm fair value change income to be -173 million yuan.

Huiyu Pharmaceutical releases a correction announcement on the performance report for 2025. During the reporting period, the company's invested enterprise Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. was listed on the Hong Kong Stock Exchange. The fair value change income of the company's directly held equity in Tongyuan Kang Pharmaceutical Co., Ltd. during the reporting period was -173 million yuan. Other than the above correction, the original announcement remains unchanged. The company apologizes for any inconvenience caused to investors and sincerely asks for their understanding.